SPLENECTOMY IN THE TPO MIMETIC ERA – STILL REASONABLE APPROACH?
Author(s): ,
Eva Koní?ová
Affiliations:
1st Department of Medicine - Department of Hematology,First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague,Prague,Czech Republic
,
Olga ?erná
Affiliations:
Department of Internal Medicine and Hematology,3rd Faculty of Medicine, Charles University,Prague,Czech Republic
,
Libor ?ervinek
Affiliations:
Department of Internal Medicine – Hematology and Oncology,University Hospital and Masaryk University,Brno,Czech Republic
,
Tomáš Kozák
Affiliations:
Department of Internal Medicine and Hematology,3rd Faculty of Medicine, Charles University,Prague,Czech Republic
,
Martin Šimkovi?
Affiliations:
2nd Department of Medicine-Department of Hematology,Charles University Hospital and Faculty of Medicine,Hradec Králové,Czech Republic
Marek Trn?ný
Affiliations:
1st Department of Medicine - Department of Hematology,First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague,Prague,Czech Republic
EHA Learning Center. Konirova E. Jun 12, 2015; 100116
Disclosure(s): First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague
1st Department of Medicine - Department of Hematology
Dr. Eva Konirova
Dr. Eva Konirova

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: E1418

Type: Eposter Presentation

Background

Immune thrombocytopenia (ITP) is an acquired, immunologically determined disease characterized by a decrease in platelet count and the associated increased risk of bleeding. The spleen plays a major role in the pathogenesis of ITP, it is the site of antibody production and often the major site of antibody-mediated platelet destruction. Splenectomy was the first method for ITP therapy and has long been the standard second-line treatment for adults with ITP who do not respond to corticosteroids. Recent advances in the understanding of etiopathogenetic mechanisms of ITP led to the development of novel therapies and changed the role of splenectomy in the management of ITP.



Aims

Describe the population indicated for splenectomy (before and after new guidelines)

Evaluated efficacy and safety of splenectomy and therapeutic possibilities for refractory patients



Methods

We retrospectively analyzed the data of 98 patients with primary ITP from four Czech hematological centers who underwent splenectomy between years 1995 and 2014. The response was evaluated according to the ITP International Working Group guidelines.



Results

In total, 98 patients (66% females) underwent splenectomy for ITP between 1995 and 2014 in four Czech hematological centers. The median age at diagnosis was 36 years (range 6-72) and median age at splenectomy was 38 years (range 17-73). 56% patients who were splenectomized before year 2010 had chronic ITP while 72% patients had chronic ITP if the splenectomy was performed after year 2010. Minority of patients had newly diagnosed ITP, in a subgroup of patients splenectomized before year 2010 it was 19% and in a subgroup of patients splenectomized after year 2010 were none with newly diagnosed ITP's. While the median interval between diagnosis and splenectomy in patients who were splenectomized before 2010 was 13 months, the median interval in patients who were splenectomized after 2010 was longer (32 months). After 2010, splenectomy was used most often as a third-line treatment. 25 patients in our group underwent labelled platelet scanning before splenectomy, majority of them had splenic uptake. The median platelet count before splenectomy was 65 x 109/l (range 1-330 x 109/l). 77 patients (79%) were prophylactic vaccinated against encapsulated bacterial pathogens. 61% of patients underwent splenectomy with an open technique and 39% with a laparoscopic technique and the rate of laparoscopic splenectomies increased over time. Of the 98 patients, 10 (11%) achieved a response (R) and 83 (84%) a complete response (CR), the overall response rate was 95%. 28 (29%) patients relapsed after a median time 6 months (range 1-125). 8 patients (8%) experienced peri-operative and 3 patients (3%) post-splenectomy complications. In 33 patients (34%) splenectomy was not successful because of the relapse or lack of response, but new treatment options especially TPO mimetics improved the outcome of these refractory patients.



Summary

Splenectomy is an effective treatment for ITP with two thirds of patients achieving long-term response and still has a place in the management of ITP. Recent trend is to postpone splenectomy until the chronic phase of the disease.



Keyword(s): Immune thrombocytopenia (ITP), Splenectomy

Session topic: E-poster
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings